ArrayGenomics is leading the revolution in bladder cancer surveillance ArrayGenomics offers a robust, highly sensitive, non-invasive, molecular monitoring test using micro-array CGH technology. For those affected with BC, cystoscopy is often seen as the gold standard for monitoring of BC. Our BCA-1 test has shown to be more sensitive and with a high NPV (Negative Predictive Value). We offer clinicians and patients the safety of monitoring the evolution of your conditions without the pain or the stress that comes with cystoscopy. The future of bladder cancer surveillance is already here. Come and be part of the solution
| Website | http://www.arraygenomics.net |
| Employees | 2 (1 on RocketReach) |
| Founded | 2003 |
| Technologies |
JavaScript
,
HTML
,
Twitter
+6 more
(view full list)
|
| Industry | Biotechnology Research |
| Keywords | Bladder Cancer, Cancer Surveillance, Early Cancer Detection, Urology Diagnostics, Cancer Diagnostics, Genomic Testing, Molecular Diagnostics, Liquid Biopsy, Cancer Biomarkers, Genetic Testing, Oncology Diagnostics, Personalized Medicine, Disease Monitoring, Medical Diagnostics, Health Diagnostics, Genomics Research, Clinical Diagnostics |
Looking for a particular ArrayGenomics employee's phone or email?
Steven Jones is the Director of ArrayGenomics.
1 people are employed at ArrayGenomics.